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BACKGROUND: Recurrence of glioma frequently occurs within the marginal area of the surgical cavity due to invading residual cells.
5-Aminolevulinic acid (5-ALA) fluorescence-guided resection has been used as effective therapeutic modalities to improve
discrimination of brain tumour margins and patient prognosis. However, the marginal areas of glioma usually show vague
fluorescence, which makes tumour identification difficult, and the applicability of 5-ALA-based photodynamic therapy (PDT) is
hampered by insufficient therapeutic efficacy in glioma tissues.
METHODS: To overcome these issues, we assessed the expression of ferrochelatase (FECH) gene, which encodes a key enzyme that
catalyses the conversion of protoporphyrin IX (PpIX) to heme, in glioma surgical specimens and manipulated FECH in human glioma
cell lines.
RESULTS: Prominent downregulation of FECH mRNA expression was found in glioblastoma tissues compared with normal brain
tissues, suggesting that FECH is responsible for PpIX accumulation in glioblastoma cells. Depletion of FECH by small interference
RNA enhanced PpIX fluorescence after exposure to 5-ALA concomitant with increased intracellular PpIX accumulation in glioma
cells. Silencing of FECH caused marked growth inhibition and apoptosis induction by PDT in glioma cells.
CONCLUSION: These results suggest that knockdown of FECH is a potential approach to enhance PpIX fluorescent quality for
optimising the subjective discrimination of vague fluorescence and improving the effect of 5-ALA-PDT.
British Journal of Cancer (2011) 104, 798–807. doi:10.1038/bjc.2011.12 www.bjcancer.com
Published online 8 February 2011
& 2011 Cancer Research UK
Keywords: glioma; ferrochelatase; 5-aminolevulinic acid; fluorescence; photodynamic therapy
                                                       
Glioma is the most common primary malignant brain tumour in
adults, characterised by rapid proliferation, marked infiltration,
and poor prognosis (Lefranc et al, 2006; Iacob and Dinca, 2009).
Recurrence of glioma occurs within B2cm of the margins of the
resected cavity due to its invasive character (Wallner et al, 1989;
Aydin et al, 2001). Therefore, methods that easily detect tumour
margins during the operation might be of benefit. 5-Aminolevulinic
acid (5-ALA) fluorescence-guided resection of glioma is a rapidly
growing novel approach to improve the extent of tumour resection
with broad application in both pre-clinical and clinical settings
(Stummer et al, 1998b, 1998c, 2000). Recent controlled phase III
clinical trials demonstrated that this surgical method enables more
complete resection of contrast-enhancing lesions compared with
conventional microsurgery and improves progression-free survival
in patients with malignant glioma (Stummer et al, 2006; Pichlmeier
et al,2 0 0 8 ) .
5-Aminolevulinic acid is not itself fluorescent, the metabolic
precursor of heme in the heme biosynthesis pathway, which is
metabolised into endogenous fluorescent protoporphyrin IX
(PpIX) (Kennedy and Pottier, 1992; Loh et al, 1993; Peng et al,
1997; Gossner et al, 1998; Inoue et al, 2007). An oral-intake of
5-ALA resulted in accumulation of PpIX in malignant gliomas.
Heme biosynthesis consists of a series of enzyme-catalyzed steps,
the last of which is the conversion of PpIX to heme by ferro-
chelatase (FECH), which is located in the inner mitochondrial
membrane (Ferreira et al, 1995; Kemmner et al, 2008). Exposure
to an appropriate light source with the specific wavelength causes
excitation of PpIX and allows it to become visible as red
fluorescence with bimodal function; fluorescence marker, and
5-ALA mediated-photodynamic therapy (PDT). Red fluorescence
exerts an effect as a discriminating marker to assist neurosurgeons
to visualise the extent and margins of tumours (Stummer et al,
1998c, 2006). Photodynamic therapy results in a series of
photochemical and photobiological events that cause irreversible
damage to tumour cells. Nowadays, PDT is widely used as an
effective adjuvant therapy for treating various cancers, including
malignant glioma (Muller and Wilson, 1995; Kostron et al, 1996;
Onuki et al, 2004).
However, successful glioma resection often depends on the
neurosurgeon’s ability to distinguish residual tumour tissue from
surrounding brain tissue even under the assistant with PpIX
fluorescence. The marginal area containing infiltrating glioma cells
shows vague fluorescence because the density of the glioma cells is
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slow and heterogeneous, resulting in insufficient 5-ALA uptake and
PpIX accumulation (Utsuki et al, 2006). On the other hand,
unfortunately, current 5-ALA–PDT protocols have yet to be widely
established in clinical treatment for glioma. This may partly be due
to limitations in current PDT regimens and partly due to the
therapeutic efficacy of 5-ALA–PDT in pre-clinical settings (Norum
et al, 2009). If the specificity and selectivity of 5-ALA–PDT could
be improved in glioma tissue, 5-ALA–PDT would probably be
regarded as a promising and competitive alternative in glioma
treatment (Angell-Petersen et al, 2007). To improve the accuracy
of vague fluorescence discrimination and 5-ALA–PDT efficacy,
we attempted to accumulate intracellular PpIX under fixed 5-ALA
concentrations and time intervals by manipulating FECH gene
expression.
In this study, we examined FECH expression and localisation in
glioma surgical specimens and the correlation between FECH
expression and PpIX accumulation in glioma cell lines. To enhance
5-ALA fluorescence quality and 5-ALA–PDT sensitivity, we
applied small interfering RNA (siRNA) of FECH to induce PpIX
accumulation. The results suggest that FECH knockdown
enhanced the molecular imaging quality of 5-ALA and the effect
of 5-ALA–PDT.
MATERIALS AND METHODS
Antibodies and reagents
Cell culture media, sodium dodecyl sulphate (SDS)–polyacryl-
amide gel, polyvinylidene difluoride (PVDF) membrane, and
bovine serum albumin (BSA) were purchased from Invitrogen
(Carlsbad, CA, USA). Rabbit polyclonal antibody and mouse
polyclonal antibody against FECH were purchased from LifeSpan
Biosciences (Seattle, WA, USA) and Abcam (Cambridge, MA,
USA), respectively. Small interfering RNA specific to human
FECH and luciferase as a control was purchased from Qiagen
(Gaithersburg, MD, USA). 5-Aminolevulinic acid hydrochloride
was purchased from Sigma (St Louis, MO, USA) and dissolved in
deionised water to make a 60-mM stock, maintained at  201C away
from light until use as described previously (Au et al, 2006).
Clinical samples and histology
Following an institutional review board-approved protocol, fresh
human brain tumour tissues were obtained from 66 patients who
had been treated neurosurgically. Non-neoplastic control brain
tissues were identified far from the tumour margins. Brain
tumours were extirpated from the centre of the tumour, classified
and characterised according to the revised World Health
Organisation classification (Louis et al, 2007). The 66 gliomas
consisted of 17 diffuse astrocytomas, 8 anaplastic astrocytomas,
and 41 glioblastomas. All of the tumour tissues were obtained
during the primary resection, and none of the patients had been
subjected to chemotherapy or radiation therapy before the
therapeutic removal of gliomas. Tissue samples were obtained
and immediately frozen in liquid nitrogen. Samples were
maintained at  801C until use.
Cell line and cell culture
Human glioma cell lines SNB19, U87 (American Type Culture
Collection, Manassas, VA, USA), and G112 (Westphal et al, 1988;
Giese et al, 1994) were cultured at 371C in a humidified CO2
incubator with DMEM, 10% fetal bovine serum (FBS), and
1% penicillin–streptomycin. The cells were passaged twice weekly,
and once they were nearly confluent, they were released with
0.25% trypsin–EDTA.
Immunohistochemistry
Immunohistochemistry was done using an avidin–biotin immuno-
peroxidase technique to stain 5-mm sections as previously
described (Nakada et al, 2005). Rabbit polyclonal antibody against
human FECH was used at a dilution of 1:1000 and non-immune
rabbit IgG was used as a negative control.
Immunofluorescence analysis
A total of 5 10
5 cells transfected with siRNA for 72h were seeded
onto a 10-well slide (2000 per well) and incubated at 371C with 5%
CO2. After 4h, they were fixed with 4% paraformaldehyde for
20min and 0.2% Triton X-100 for 5min at room temperature.
Immunostaining was performed by incubating the slides with
mouse polyclonal anti-FECH antibody (1:500) at 41C for 2h,
followed by incubation with Alexa Fluor 488 goat anti-mouse
antibody (1:500; Invitrogen) for 1h at room temperature in the
dark. Finally, the sections were washed with Tris-buffered saline
Tween-20 and cell images were captured on a fluorescence
microscopy (AX 80, Olympus, Tokyo, Japan).
Quantitative real-time–PCR (QRT–PCR)
Gene expression was quantified by QRT–PCR on a LightCycler
using MasterPLUS SYBR Green (Roche Diagnostics, Indianapolis,
IN, USA) as described previously (Nakada et al, 2006). The sense
primer of human FECH (Genbank accession number NM_000140)
was 50-TGCACTCAAAATTTGCTTCG-30; the antisense primer
was 50-GGCAAAACCCCATCTCTACA-30 (amplicon size, 250bp).
Another primer set of FECH was also used: sense, 50-GATGAATT
GTCCCCCAACAC-30; antisense, 50-GCTTCCGTCCCACTTGATTA-30
(amplicon size, 208bp); b-actin (NM_001101): sense, 50-CTACAATG
AGCTGCGTGTGGC-30; antisense, 50-CAGGTCCAGACGCAGGATG
GC-30 (amplicon size, 271bp). The PCR data were analysed by
LightCycler analysis software as described previously (Nakada et al,
2006).
Silencing of FECH with siRNA
The target sequence 1 of siRNA specific to human FECH was
(2044–2064bp) 50-CCCAAGGGTAATAAACGTGTA-30; sequence 2
was (1008–1028bp) 50-CCGACTGGTGTGGCAATCCAA-30. The
cells were transfected with either FECH siRNA or control luciferase
using Lipofectamine 2000 (Invitrogen). The confluent cells seeded
into 6-well plates were transfected with the respective siRNA and
collected after 72h by a scraper or with trypsin–EDTA. The effects
of siRNA lasted for at least 96h as determined by QRT–PCR and
immunofluorescence analysis (Nakada et al, 2005).
Western blot analysis
Western blot analysis was performed on the PVDF membrane
according to the standard procedure as described previously
(Nakada et al, 2005; Yoshida et al, 2009). Rabbit polyclonal
antibody against FECH was used at a dilution of 1:1000.
Protoporphyrin IX fluorescence molecular imaging
After transfection with FECH siRNA, the cells were harvested,
counted, and plated (5 10
5) on microscope coverslips in 100-mm
dishes, and then incubated with serum-free DMEM with 12-h
adherence. After adherence was achieved, the medium was
immediately replaced with serum-free DMEM containing 5-ALA
solution (final concentration: 400mM) (Hanania and Malik, 1992;
Inoue et al, 2007; Miyake et al, 2009). After incubation for 6h, cells
on the coverslip were fixed with 4% paraformaldehyde in
phosphate buffer solution (PBS) for 10min at room temperature,
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swashed with PBS twice, and mounted with mounting solution with
another coverslip (Sinha et al, 2006). Protoporphyrin IX-specific
fluorescence in the glioma cells was captured by fluorescence
microscopy (BX 50, Olympus) and a digital camera (DP70,
Olympus) under the same exposure time of the illumination
source: phase-contrast images, 1/60s, and PpIX molecular images,
20s. Intracellular PpIX fluorescence was excited at 488nm and
molecular images were collected in the red channel through a 590-
nm long-pass filter.
Protoporphyrin IX fluorescence spectral intensity analysis
The transfected cells were harvested and counted, and 5 10
5 cells
were incubated with serum-free DMEM with 12-h adherence. After
adherence was achieved, the medium was immediately replaced
with serum-free DMEM containing 5-ALA solution (final concen-
tration: 400mM) for 6h at 371C (Hanania and Malik, 1992). At the
end of the incubation period, the cells were detached from the
plates and centrifuged at 6g and the pellets were resuspended in
100ml extraction solution (50mM Tris-HCl, pH 7.5; 100mM NaCl;
2.5% Triton X-100), shaken for 1min at room temperature, and
centrifuged at 1400g for 5min. The supernatant was transferred
into 300ml ethyl acetate and glacial acetic-acid solution (v/v, 2:1).
After 1-min shaking, the supernatant was added to 300ml of 0.6 M
NaOH and centrifuged at 1400g for 2min, and the upper phase
was dissolved in 300ml of 0.5 M HCl and centrifuged at 1400g for
2min. After centrifugation, the lower phase was collected and read
for PpIX fluorescence using an SVLD-M1 (SBI ALApromo Co., Ltd,
Tokyo, Japan; excitation, 400nm; emission, 605nm). Accessory
software (BW-Spec V 3.26; Newark, NJ, USA) was used to analyse
the PpIX fluorescence spectral intensity data. The two character-
istic PpIX fluorescence spectras were detected, a sharp peak at
600–640nm and a slightly broader peak at 700–710nm as
described previously (Loh et al, 1993). The PpIX fluorescence
spectral intensity increased between 600 and 710nm in a wide
wave band due to exposure to the specific wavelength. We
observed the two characteristic peaks (635 and 705nm), indicating
that the PpIX fluorescence was in the cells (Stummer et al, 1998a).
Using the software, the steep rise in intensity at the 605-nm peak
was used to calculate the difference in intensity at 600–640nm
of the cell line sample. The results are expressed as the mean
of triplicate representative experiments (Utsuki et al, 2008).
Cell proliferation assay
The Alamar Blue assay (Biosource, Camarillo, CA, USA) was used
to assess cell proliferation as described previously (Nakada et al,
2005). After transfection with either control or FECH siRNA
together treated with 400mM 5-ALA for 6h, 5 10
5 cells were
exposed to two different fluences of light at 630nm, 0.5Jcm
 2 and
1Jcm
 2, as described previously (Inoue et al, 2007; Madsen et al,
2009). After illumination, the medium was immediately replaced
with DMEM containing 10% FBS. After incubation for 24h at 371C,
1000 cells of each population were seeded in 96-well plastic plates
in 200ml of culture medium supplemented with 0.1% FBS (Hanania
and Malik, 1992). The plates were incubated for 4h at 371C and
Alamar Blue (Biosource) was added in a volume of 20ml (10% of
total volume) to the cells and incubated. The plate was read on a
fluorescence plate reader (excitation, 530nm; emission, 590nm) at
24, 48, 72, and 96h. Average absorbance values were calculated.
Cell apoptosis analysis
For analysis of apoptosis by 5-ALA–PDT, cells underwent the
same pretreatment as described above in the cell proliferation
assay. After incubation with DMEM containing 10% FBS for 24h
at 371C, all cells were harvested and determined by staining with
a human Annexin V FITC Apoptosis Detection Kit (Bender
MedSystems, Burlingame, CA, USA), according to the manufac-
turer’s instructions. Briefly, G112 and SNB19 cells were trypsi-
nised, pelleted by centrifugation, and resuspended in Annexin V
binding buffer. Fluorescein Isothiocyanate-conjugated Annexin V
(1mgml
 1) and propidium iodide (20mgml
 1) were added to cells,
which were incubated for 10min at room temperature in the dark.
At least 20000 stained cells were analyzed on a FACS Caliber
system (Becton Dickinson, Bedford, MA, USA) for each
determination. The data were analyzed using Cell Quest software
(Becton Dickinson).
Statistics
Differences of FECH expression between various human astrocytic
tumours and normal brain tissues were presented as mean±s.e.
and analyzed by Welch’s test using Graph Prism software
(GraphPad Software, San Diego, CA, USA). Other data were
expressed as mean (s.d.) and compared by Student’s t-test.
Probability values o0.05 were considered significant.
RESULTS
Ferrochelatase mRNA expression and immunolocalisation
in various human astrocytic tumours
The expression levels of FECH in human normal brain tissues
(n¼15) and glioma specimens (n¼66) were evaluated by
QRT–PCR using b-actin mRNA as an internal reference for
normalisation (Figure 1A). Ferrochelatase expression seemed to be
reduced in glioma tissues compared with normal brain tissues. The
expression levels of FECH mRNA were significantly lower in
glioblastoma tissues (mean±s.e., 1.21±0.40; n¼41) than that in
normal brain tissues (5.71±2.36; Po0.05; n¼15), diffuse astro-
cytoma tissues (3.89±0.92; Po0.05; n¼17) and anaplastic
astrocytoma tissues (4.60±0.75; Po0.005; n¼8).
Cells expressing FECH in normal brain and glioblastoma
specimens were identified using immunohistochemistry. We can
easily gain objective demarcation line between normal brain tissue
and tumour tissue according to the density of FECH staining
(Figure 1B, Panel a). Ferrochelatase was predominantly immuno-
localised in the majority of neurons and astrocytes in normal brain
specimens, whereas faint staining was detected in neoplastic
astrocytes in glioblastoma specimens (Figure 1B). The density of
FECH-positive cells was significantly lower in glioblastoma speci-
mens compared with normal brain specimens under random fields
of microscopic observation at the same magnification (Figure 1B,
Panels b and c). This result was consistent with that of the
QRT–PCR analysis.
Ferrochelatase mRNA and protein expression in glioma
cell lines
To assess the efficiency of FECH siRNA in glioma cell lines,
appropriate cell lines that express high levels of FECH should be
chosen. Ferrochelatase mRNA expression in G112, SNB19, and U87
glioma cell lines was determined by QRT–PCR. The expression
levels of FECH mRNA in these three glioma cell lines were
significantly different, being highest in G112 and lowest in U87
(Figure 2A). Immunoblotting with a specific antibody against
FECH was performed using the same cell lines. An B42-kDa single
band of FECH (Ohgari et al, 2005) was clearly detected in the
G112 and SNB19 cell lines, but faintly detected in U87 glioma
cells (Figure 2B). This result was consistent with that of the
QRT–PCR analysis. Thus, the G112 and SNB19 cell lines, in which
FECH is highly expressed, were chosen for the FECH silencing
experiment.
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sProtoporphyrin IX fluorescence in glioma cell lines
To discern the optimal time point for exposing 5-ALA in glioma
cell lines, time-dependent accumulation of PpIX was quantified.
We detected a sharp peak at 605nm, indicating the PpIX
characteristic fluorescence spectra, in G112, SNB19 and U87 cells
(Figure 3A). The spectral intensity of PpIX fluorescence increased
in a time-dependent manner after 5-ALA exposure. In U87 and
SNB19 cells, PpIX fluorescence intensity reached a plateau at B6h
(Figure 3B). Therefore, 6h was chosen as the optimal time point
for 5-ALA exposure. The intensity of PpIX fluorescence in U87
cells was higher than that in G112 and SNB19 cells, suggesting that
U87 cells are more susceptible to 5-ALA than G112 and SNB19
cells. This is consistent with the data in Figure 2, showing a lower
FECH expression in U87 cells than in G112 and SNB19 cells. Next,
molecular imaging of PpIX was captured by fluorescence
microscopy in the G112, SNB19 and U87 cells after 6-h 5-ALA
exposure. PpIX fluorescence was not visualised in wild-type glioma
cells without 5-ALA; however, PpIX-derived metabolic fluores-
cence was observed in the cytoplasm of the glioma cells after
exposure to 5-ALA (Figure 3C). The degree of fluorescence
intensity in the cell lines seemed to be consistent with the data
in Figures 3A and B. These results indicate that exogenous
exposure to 5-ALA increased accumulation of PpIX in glioma cells,
which improved intensity of the fluorescence and that the intensity
seems to be dependent of the endogenous level of FECH.
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Figure 1 Expression levels of FECH mRNA in various human gliomas and immunolocalization of FECH in glioblastoma and normal brain tissues.
(A) Relative mRNA expression levels of the FECH gene (FECH mRNA: b-actin mRNA ratios) in normal brains (NBs), diffuse astrocytomas (DA), anaplastic
astrocytomas (AA), and glioblastomas (GBM) were analyzed by QRT–PCR. FECH mRNA expression levels were significantly lower in glioblastomas
compared with normal brains, diffuse astrocytomas and anaplastic astrocytomas (*Po0.05; ***Po0.005). Data are expressed as means±s.e.
(B) Immunolocalization of FECH in invading edge of glioblastoma (upper left: glioblastoma; lower right: normal brain, panel a), glioblastoma (panel b) and
normal brain tissues (panels c and d). Paraffin sections were immunostained with anti-FECH antibodies (panels a, b and c) or non-immune rabbit IgG
(panel d). Note that FECH is immunolocalized in the normal astrocytes (panel c, arrow head) and neurons (panel c, thin arrows). Faint staining is detected
in neoplastic astrocytes (panel b, thick arrows), whereas no staining is observed in the normal brain with non-immune IgG (panel d).
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Figure 2 FECH mRNA and protein expression in glioma cell lines. (A) QRT–PCR was used to determine FECH mRNA expression levels in G112,
SNB19, and U87 glioma cell lines. Data are expressed as mean (s.d.) of triplicate experiments. (B) Western blotting shows FECH protein in the glioma cell
lines. The total cell lysates were immunoblotted with FECH and b-actin antisera.
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sProtoporphyrin IX accumulation after FECH silencing
To confirm the effect of FECH silencing, two siRNAs were
transfected into SNB19 and G112 cells to specifically knockdown
FECH mRNA expression. The mRNA levels of FECH at 72h after
siRNA transfection were determined by QRT–PCR. The knock-
down ratio of FECH by both siRNA sequence 1 and sequence 2 was
more than 50% in both cell lines (Figure 4A). Figure 4B shows
FECH protein labelled by Alexa Fluor green fluorescence in G112
and SNB19 cells transfected with FECH siRNA or luciferase
control. The decrease in green fluorescence intensity suggests
depletion of FECH protein in cells transfected with FECH siRNA.
These data suggest that sufficient FECH silencing was obtained
using FECH siRNA sequence 1 and sequence 2.
Next, to investigate whether FECH interference causes abundant
accumulation of PpIX after 5-ALA exposure, cells transfected with
control or FECH siRNA were treated with 5-ALA. Expectedly, PpIX
fluorescence spectral intensity was significantly increased in cells
transfected with FECH siRNA sequence 1 and sequence 2
compared with control luciferase-siRNA (Figures 5A and B). The
increasing ratio of PpIX fluorescence spectral intensity after
FECH interference is higher in G112, which was more sensitive to
FECH siRNA than SNB19. In G112 cells, transfection of siRNA
sequence 2 (mean±s.d., 28.80±4.70) induced a higher level of
PpIX fluorescence spectral intensity, B400% of the control
(7.27±0.48; Po0.01). In SNB19 cells, the effect of siRNA sequence 1
(48.36±2.23) and sequence 2 (42.65±5.10) was similar in that
the relative intensity of transfection with FECH siRNA was 200%
greater than that of the control (18.61±1.52, Po0.005; Po0.01,
respectively, Figure 5B). These data demonstrated that depletion of
FECH resulted in a significant increase of intracellular PpIX
accumulation in glioma cells after 5-ALA exposure.
Ferrochelatase silencing enhances PpIX molecular imaging
quality
We then investigated whether FECH silencing enhances PpIX
molecular imaging quality. We captured fluorescence images of
cells transfected with siRNA using fluorescence microscopy after
exposure to 5-ALA for 6h. Bright and clear red fluorescence were
visualised in glioma cells transfected with FECH siRNA compared
with control (Figure 5C). High-contrast strong red fluorescence
was diffusely localised to the cytoplasm of glioma cells transfected
with FECH siRNA. Furthermore, we can clearly discriminate
between glioma cell cytoplasm and nuclei at higher magnification.
These data indicate that we can obtain high molecular imaging
quality of PpIX fluorescence in glioma cells by silencing FECH.
Ferrochelatase knockdown enhances 5-ALA-based PDT
efficacy
Furthermore, we performed a proliferation assay to examine the
influence of FECH silencing on 5-ALA–PDT. According to
the proliferation curve diagram, light-irradiated cells transfected
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Figure 3 PpIX accumulation in glioma cells after 5-ALA exposure. (A) PpIX fluorescence spectra tracing at various time points. The peak at 605nm
(arrow) indicates the characteristic PpIX fluorescence spectra. x-axis: wavelength; y-axis: relative intensity. (B) The time-dependent PpIX accumulation curve
was drawn according to the results of (A). PpIX fluorescence spectral intensity reached a plateau at B6h in U87 and SNB19. The data are based on three
independent experiments, and the error bars show mean (s.d.). (C) Molecular imaging of PpIX was visualised by fluorescence microscopy in G112, SNB19,
and U87 cells that were incubated for 6h with 5-ALA. Upper panels: phase-contrast images; lower panels: PpIX molecular images, insets: higher
magnification.
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swith FECH siRNA showed a pronounced inhibitory effect on cell
proliferation in both G112 and SNB19 cells (Po0.005, Figure 6).
Furthermore, proliferation was suppressed more with 1Jcm
 2
light fluence than with 0.5Jcm
 2 light fluence in both cell lines.
These data suggest that FECH knockdown enhances the PDT effect
in a light fluence-dependent manner.
Apoptosis was quantified by flow-cytometric analysis. The
results show that FECH silencing significantly increased the
proportions of both early (Annexin V-positive, PI-negative) and
late (Annexin V-positive, PI-positive) apoptotic cells induced by
5-ALA–PDT. In G112 cells with 0.5Jcm
 2 light fluence, the
proportion of early apoptotic cells was 15.4 and 13.4% in the
FECH siRNA sequence-1 and sequence-2 group, respectively,
much more than the 3.1% seen in the negative control (Figure 7).
Transfected SNB19 cells responded similarly. Furthermore, the
number of apoptotic cells was significantly higher with 1Jcm
 2
light fluence than with 0.5Jcm
 2 light fluence. These results
suggest that 5-ALA–PDT enhancement by FECH knockdown can
be attributed to induction of apoptosis.
DISCUSSION
This study has demonstrated significant downregulation of FECH
mRNA expression in glioblastomas compared with normal brain
tissues. Studies have shown that low expression or molecular
defects of FECH in malignant tumours, such as colon cancer and
urothelial cancer, is correlated with intracellular PpIX accumu-
lation (Peng et al, 1997; Miyake et al, 2009). Currently, no data
have been reported concerning the metabolism of 5-ALA in
glioma, although 5-ALA fluorescence-guided glioma resection is
well established. In this study, we showed that SNB19 cells, which
expressed lower levels of FECH than G112 cells, accumulated more
PpIX than G112 cells after exposure to 5-ALA. Ferrochelatase
silencing in SNB19 and G112 cells promoted PpIX accumulation
and enhanced visible red fluorescence in vitro. Together, the
in vitro and in vivo data indicate a strong correlation between FECH
expression and PpIX accumulation. Our results are consistent with
clinical observations of glioblastomas commonly showing high-
intensity PpIX fluorescence. Thus, this study is the first to reveal
that FECH has a role in the metabolism of 5-ALA in glioma.
It remains possible that other molecules, not studied here, may
contribute to the metabolism of 5-ALA in glioma. Pre-clinical and
clinical studies suggest that the accumulation of PpIX in glio-
blastoma cells may be caused by various factors (Norum et al,
2009). As the normal blood–brain barrier (BBB) is impermeable
to 5-ALA, the compromised BBB in glioblastoma tissue is
necessary for 5-ALA to cross BBB to get to the glioblastoma cells.
5-Aminolevulinic acid has to cross the tumour cells through the
transporters, such as peptide transporter 2 (PEPT2), which is
the primary transporter responsible for the astrocytic uptake
of 5-ALA (Rodriguez et al, 2006; Xiang et al, 2006). Actually
PEPT2 is overexpressed in glioblastoma cells (our unpublished
data). Several molecules are known to be involved in the heme
synthesis pathway in tumour cells (Ennis et al, 2003). A previous
report has indicated that decreased PpIX levels and therapeutic
effect of 5-ALA–PDT were induced by the silencing of heme
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Figure 4 Efficiency of FECH siRNA silencing in glioma cell lines. (A) FECH siRNA sequence 1 and sequence 2 were transfected into G112 and SNB19
cells. Luciferase was transfected as a negative control, and total RNA was extracted from the cells 72h later for cDNA synthesis. FECH mRNA expression
after transfection was determined by QRT–PCR. (B) Micrographs of FECH protein labeled by green-fluorescent Alexa Fluor 488 dye (Invitrogen, Carlsbad,
CA, USA) in G112 and SNB19 glioma cells transfected with siRNA. Green fluorescence intensity significantly decreased in FECH siRNA sequence 1 and
sequence 2 compared with control siRNA. Representative micrographs of three independent experiments are shown.
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Figure 5 PpIX fluorescence spectra analysis and molecular images of glioma cells transfected with siRNA. (A) PpIX fluorescence spectra tracing at 6h
after FECH or luciferase siRNA transfection and incubation with 400mM 5-ALA. The peak at 605nm (arrow) indicates the characteristic PpIX fluorescence
spectra. x-axis: wavelength; y-axis: relative intensity. (B) Histogram of PpIX relative fluorescence intensity of cells transfected with siRNA after 6-h exposure
to 400mM 5-ALA. PpIX fluorescence spectral intensity was significantly increased in the cells transfected with FECH siRNA sequence 1 and sequence 2
compared with that in the cells transfected with control siRNA (*Po0.05; **Po0.01; ***Po0.005). Data are expressed as mean (s.d.) of triplicate
experiments. (C) PpIX molecular images of glioma cells transfected with FECH siRNA. Molecular images of PpIX were visualized by fluorescence
microscopy in G112 and SNB19 glioma cells. After 72-h FECH siRNA transfection, the cells were exposed to 400mM 5-ALA for 6h. Note that strong red
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soxygenase (HO) (Miyake et al, 2009). Analysis of responsible
molecules for the metabolism of 5-ALA in glioma cells is ongoing
in our laboratory.
Objective quantification of PpIX is critical to assess the changes
in PpIX fluorescence intensity, but it is difficult to achieve. In this
study, we measured intracellular PpIX using fluorescence spectral
intensity analysis, which allows an observer to check the specified
PpIX spectra on a monitor by reading the PpIX fluorescence
wavelength peak. Compared with spectrofluorometric (Sinha et al,
2006; Miyake et al, 2009) and flow-cytometric analysis (Ickowicz
Schwartz et al, 2004; Inoue et al, 2007), this analysis has prominent
advantages for PpIX fluorescence quantification: (1) directly and
objectively, it has a characteristic spectra tracing that indicates
specified fluorescence (e.g., the sharp peak at 605nm indicative of
the characteristic PpIX fluorescence spectra); (2) it is simple
procedure and requires only that an investigator recognise the
spectra and read the result; and (3) it is a potential diagnostic tool
to assist with fluorescence-guided resection. Ours and recent other
studies suggest that the usefulness of fluorescence spectral
intensity analysis (Utsuki et al, 2006, 2008) may facilitate PpIX
recognition by this system in both pre-clinical and clinical settings.
With our convincing evidence of a causal relationship between
FECH expression and PpIX accumulation, we assumed that the
FECH enzyme may function as a promising molecular target to
increase PpIX accumulation for clinical application. As we
expected, FECH siRNA caused abundant PpIX accumulation and
more visible red fluorescence in glioma cells, suggesting that FECH
silencing can improve PpIX fluorescence discrimination accuracy.
Depending on the high-contrast intensity and high-resolution
imaging, neurosurgeons can potentially obtain the best detailed
diagnostic information for facilitating fluorescence recognition
and localisation.
Furthermore, we assessed the effect of FECH silencing on
5-ALA-PDT efficacy. Generally, PDT efficacy depends on para-
meters, such as photosensitizing agent, light fluence, illumination
time, oxygen, photosensitizer concentration, and intrinsic tissue
sensitivity to the PDT effect (Sinha et al, 2006; Madsen et al, 2009).
In our study, FECH siRNA significantly enhanced 5-ALA-PDT
efficacy in glioma cells caused by marked growth inhibition and
abundance of apoptotic cells under unchanged above parameters
except for photosensitizer (PpIX) concentration. It is highly likely
that intrinsic PpIX level is critical for the 5-ALA-PDT effect and
that the radical cause of enhanced 5-ALA–PDT by FECH silencing
is the high levels of PpIX. Currently, the exact mechanism of
5-ALA–PDT is not known. In our study, accumulated PpIX within
the glioma cells may have caused irreversible photodamage by
exposure to a specific wavelength. Recent studies have shown that
5-ALA–PDT-induced photodamage causes mitochondrial and
nuclear DNA damage; subsequently, massive apoptosis occurs
because of mitochondrial release of cytochrome c and activation of
caspase in glioma cells (Inoue et al, 2007; Karmakar et al, 2007).
Further studies will be required to explore the detailed mechanism
of 5-ALA–PDT-induced photodamage in human glioma cells.
RNA interference (RNAi) offers great potential, not only for
in vitro target validation but also in vivo as a novel therapeutic
strategy based on highly specific and efficient silencing of a target
gene in tumour therapy (Grzelinski et al, 2006). This study is the
first to demonstrate that FECH siRNA, which is a non-invasive and
safe molecular agent because it led to an accumulation of intrinsic
and non-toxic PpIX within the cytoplasm, offers the promise of
being an exciting new tool with great potential to enhance the
efficiency of 5-ALA fluorescence and 5-ALA–PDT in glioma cells.
However, at the present time, application of siRNAs in vivo is
severely limited by their instability and poor delivery into target
cells and target tissues (Guo et al, 2010). Currently, various
potential methods for delivering siRNA into target cells have been
developed. Pardridge and his collaborators have applied immuno-
liposomes containing a short hairpin RNA (shRNA) expression
vector against the epidermal growth factor receptor (EGFR) to
suppress brain tumour proliferation with a single intravenous
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Figure 6 Proliferation curve of glioma cells transfected with FECH siRNA after light irradiation. Luciferase and FECH siRNA sequence 1 and sequence
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 2 or
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sinjection in adult rats with intracranial brain tumours (Pardridge,
2004). In that system, two monoclonal antibody ligands on
liposomes were used for delivering shRNA into specific tumour
cells, one against the transferrin receptor that exists on the BBB,
and the other against the insulin receptor that was used for
subsequent targeting of the liposomes to the brain tumour cells
(Mathupala et al, 2006). Further studies are required for
development of RNAi-specific delivery systems and exploration
of high affinity receptors for glioma cells but not normal brain
tissue before clinical application.
In conclusion, we have demonstrated for the first time
that FECH siRNA enhanced the quality of 5-ALA fluorescence
imaging for optimising subjective fluorescence discrimination
and improved the efficacy of 5-ALA–PDT by increasing intrinsic
PpIX levels. The best way to enhance 5-ALA fluorescence quality
and 5-ALA–PDT efficacy in a real-time intraoperative manner
in vivo is currently under investigation in our laboratory.
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